{"id":47894,"date":"2022-09-01T13:02:05","date_gmt":"2022-09-01T11:02:05","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/kezar-life-sciences-to-participate-in-three-upcoming-investor-conferences\/"},"modified":"2022-09-01T13:02:05","modified_gmt":"2022-09-01T11:02:05","slug":"kezar-life-sciences-to-participate-in-three-upcoming-investor-conferences","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/kezar-life-sciences-to-participate-in-three-upcoming-investor-conferences\/","title":{"rendered":"Kezar Life Sciences to Participate in Three Upcoming Investor Conferences"},"content":{"rendered":"
\n

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Kezar Life Sciences, Inc.<\/a> (Nasdaq: KZR<\/a>), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that Christopher Kirk, PhD, Co-founder, President and Chief Scientific Officer, will participate in three upcoming investor conferences in September.\n<\/p>\n

\nPresentation Details:<\/b>\n<\/p>\n

\nEvent:<\/b> 2022 Wells Fargo Healthcare Conference
\n
Location:<\/b> Boston, MA
\n
Date\/Time:<\/b> Thursday, September 8, 2022, at 1:20 PM ET
\n
Format: <\/b>Fireside Chat\n<\/p>\n

\nEvent:<\/b> H.C. Wainwright 24th<\/sup> Annual Global Investment Conference
\n
Location:<\/b> New York, NY
\n
Date\/Time:<\/b> Tuesday, September 13, 2022, at 11:30 AM ET
\n
Format: <\/b>Podium Presentation\n<\/p>\n

\nEvent:<\/b> Morgan Stanley 20th<\/sup> Annual Global Healthcare Conference
\n
Location:<\/b> New York, NY
\n
Date\/Time:<\/b> Wednesday, September 14, 2022, at <\/b>9:10 AM ET
\n
Format: <\/b>Fireside Chat\n<\/p>\n

\nWebcasts from the presentations will be available on the \u201cEvents & Presentations\u201d section of the Company\u2019s website at www.kezarlifesciences.com<\/a>. Following the events, archived webcasts will be available on the Kezar website for 90 days.\n<\/p>\n

\nAbout Kezar Life Sciences<\/b>\n<\/p>\n

\nKezar Life Sciences is a clinical-stage biopharmaceutical company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders. The company is pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function to inhibit multiple drivers of disease via single, powerful targets. Zetomipzomib, its lead development asset, is a selective immunoproteasome inhibitor being evaluated in a Phase 2 clinical trial in lupus nephritis. This product candidate also has the potential to address multiple chronic immune-mediated diseases. KZR-261 is the first anti-cancer clinical candidate from the company\u2019s platform targeting the Sec61 translocon and the protein secretion pathway. An open-label dose-escalation Phase 1 clinical trial of KZR-261 to assess safety, tolerability and preliminary tumor activity in solid tumors is underway. For more information, visit www.kezarlifesciences.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestor Contact
\n
\n<\/b>
Gitanjali Jain
\n
Vice President, Investor Relations and External Affairs
\n
650-269-7523
\n
gjain@kezarbio.com<\/a><\/p>\n

Media Contact
\n
\n<\/b>
Liza Sullivan
\n
Argot Partners
\n
212-600-1902
\n
kezar@argotpartners.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that Christopher Kirk, PhD, Co-founder, President and Chief Scientific Officer, will participate in three upcoming investor conferences in September. Presentation Details: Event: 2022 Wells Fargo Healthcare Conference Location: Boston, … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-47894","6":"format-standard","7":"category-industry"},"yoast_head":"\nKezar Life Sciences to Participate in Three Upcoming Investor Conferences - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/kezar-life-sciences-to-participate-in-three-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kezar Life Sciences to Participate in Three Upcoming Investor Conferences - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that Christopher Kirk, PhD, Co-founder, President and Chief Scientific Officer, will participate in three upcoming investor conferences in September. Presentation Details: Event: 2022 Wells Fargo Healthcare Conference Location: Boston, ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/kezar-life-sciences-to-participate-in-three-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-01T11:02:05+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kezar-life-sciences-to-participate-in-three-upcoming-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kezar-life-sciences-to-participate-in-three-upcoming-investor-conferences\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Kezar Life Sciences to Participate in Three Upcoming Investor Conferences\",\"datePublished\":\"2022-09-01T11:02:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kezar-life-sciences-to-participate-in-three-upcoming-investor-conferences\\\/\"},\"wordCount\":315,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kezar-life-sciences-to-participate-in-three-upcoming-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kezar-life-sciences-to-participate-in-three-upcoming-investor-conferences\\\/\",\"name\":\"Kezar Life Sciences to Participate in Three Upcoming Investor Conferences - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2022-09-01T11:02:05+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kezar-life-sciences-to-participate-in-three-upcoming-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kezar-life-sciences-to-participate-in-three-upcoming-investor-conferences\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kezar-life-sciences-to-participate-in-three-upcoming-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kezar Life Sciences to Participate in Three Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kezar Life Sciences to Participate in Three Upcoming Investor Conferences - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/kezar-life-sciences-to-participate-in-three-upcoming-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Kezar Life Sciences to Participate in Three Upcoming Investor Conferences - Pharma Trend","og_description":"SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that Christopher Kirk, PhD, Co-founder, President and Chief Scientific Officer, will participate in three upcoming investor conferences in September. Presentation Details: Event: 2022 Wells Fargo Healthcare Conference Location: Boston, ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/kezar-life-sciences-to-participate-in-three-upcoming-investor-conferences\/","og_site_name":"Pharma Trend","article_published_time":"2022-09-01T11:02:05+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/kezar-life-sciences-to-participate-in-three-upcoming-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/kezar-life-sciences-to-participate-in-three-upcoming-investor-conferences\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Kezar Life Sciences to Participate in Three Upcoming Investor Conferences","datePublished":"2022-09-01T11:02:05+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/kezar-life-sciences-to-participate-in-three-upcoming-investor-conferences\/"},"wordCount":315,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/kezar-life-sciences-to-participate-in-three-upcoming-investor-conferences\/","url":"https:\/\/pharma-trend.com\/en\/kezar-life-sciences-to-participate-in-three-upcoming-investor-conferences\/","name":"Kezar Life Sciences to Participate in Three Upcoming Investor Conferences - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2022-09-01T11:02:05+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/kezar-life-sciences-to-participate-in-three-upcoming-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/kezar-life-sciences-to-participate-in-three-upcoming-investor-conferences\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/kezar-life-sciences-to-participate-in-three-upcoming-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Kezar Life Sciences to Participate in Three Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47894","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=47894"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47894\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=47894"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=47894"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=47894"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}